Semaglutide for Diabetic Kidney Disease (RAISE-KT Trial)

"Semaglutide was given a score of 3 by our team at Power. This is due to this medication being in Phase 3 trials, which indicates that there is not just some evidence of efficacy, but multiple rounds of data supporting safety as well."

"Semaglutide is frequently used to help patients manage their weight over the long term. Additionally, it can be employed as part of a treatment plan that includes a calorie-restricted diet, physical activity, and treating at least one other condition that is related to obesity."

"Correct, the information available on clinicaltrials.gov indicates that this study is actively looking for participants. The listing was created on 7/23/2021 and edited on 2/3/2022. They are hoping to recruit 150 patients from 2 locations."

"At the moment, 59 clinical trials concerning Semaglutide are active with 27 of them being Phase 3 research. Even though a few of the investigations for Semaglutide are happening near Loma Linda, 3899 other locations are conducting studies regarding Semaglutide."

"Yes, as of February 3rd, 2022 this clinical trial is still seeking 150 participants from two different sites, as noted on clinicaltrials.gov"

"There are 59 ongoing clinical trials for Semaglutide in 766 cities and 55 nations. The first study was completed in 2018 by Novo Nordisk A/S. It reached Phase 4 approval after involving 1387 patients. In the two years since, 123 more trials have finished."